Notice of Q1 FY22 Results

Renalytix plc

("Renalytix" or the "Company")

Renalytix to Report First Quarter Fiscal Year 2022 Financial Results on December 7

LONDON and SALT LAKE CITY, December 2, 2021 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Company will release first quarter fiscal year 2022 financial results on Tuesday, December 7, 2021, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (EST) / 1:30 p.m. (GMT).

Conference Call Details:US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551US/Canada Participant International Dial-In Number: (914) 987-7290United Kingdom International Dial-In Number: 0800 0288 438United Kingdom Local Dial-In Number: 0203 1070 289Conference ID:2495524

Webcast Registration link: https://edge.media-server.com/mmc/p/2s8cwr7x

For further information, please contact:

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.